BPC-157: benefits vs. human evidence, side effects, and FDA status in 2026

By Peptide Care Index · Sources checked October 14, 2026

BPC-157 is an experimental, lab-made peptide promoted for injury and gut healing, but human research has not shown that it heals tendons, joints, or the gut. Most of the evidence comes from animal studies, and the human studies and reports here are small or uncontrolled. As of October 14, 2026, it is not FDA-approved, and its long-term safety is unknown.

That doesn't make it useless, and it doesn't make it proven. The useful question isn't whether someone felt better. It's what was actually tested, in whom, by what route—and whether that finding applies to the result you want.

Here is the quickest way through this page:

• Wondering if it works? Start with the claim check and the human reports reviewed just below.
• Worried about risk? Go to side effects and long-term safety.
• Heard FDA "approved" it in July? It didn't. See FDA status and U.S. access.
• Holding a clinic offer? Read what to check before paying.
• Drug-tested athlete or service member? It's banned. See athletes and service members.

BPC-157 benefits: what the human evidence shows

Human BPC-157 research does include positive reports—less knee pain, less bladder pain, lower pain scores with one capsule product. But no completed, controlled human trial has shown that BPC-157 heals an injury or treats a disease, and the one placebo-controlled disease trial did not show a clear benefit. Each finding applies only to the people, form, and outcome it measured.

The two tables below are the heart of this page. The first takes the claims you'll see in ads and forums and checks each against the best human evidence. The second lists the human studies and reports we reviewed, with the details you need to judge it.

Claim check: what people say BPC-157 does vs. what's been shown in people

How to read the last column:

• Shown in people: a completed, controlled human trial found a clear benefit. No claim earns this today.
• Early human signal: small or uncontrolled human reports describe improvement, but they can't show BPC-157 caused it.
• Tested, no clear benefit: a controlled human study didn't find a clear difference from placebo.
• Animal or lab only: no human outcome data for this claim identified in our review.
• Human benefit not established: human use or improvement has been reported, but it does not establish the claimed benefit.
• Unknown: the question hasn't been measured in people.

Peptide Care Index review of the linked records, checked October 14, 2026. "Bottom line" describes the strength of human evidence for each claim. It is not a safety rating or a treatment recommendation.

Bottom line in one sentence: As of October 14, 2026, none of the treatment benefits in this table has been established by the controlled human evidence we reviewed; small studies report knee, bladder, and capsule-related pain improvements, the clinical-note preprint adds uncontrolled observations, and the ulcerative colitis trial did not show a clear benefit over placebo.

Seven human studies and reports on BPC-157

The seven rows below cover distinct groups of people reported to have received BPC-157. They differ in design, publication status, and purpose, so read each row on its own. Don't add their sample sizes together or average their results.

Sources linked in each row. All checked October 14, 2026. How we counted: one row per distinct group of people described in the studies and reports reviewed. FDA's May 2026 review describes five of these groups (rows 1–3, 5, 6); the August 2024 capsule summary was not included, and the September 2026 preprint was published later. Two abstracts about the same volunteers count as one. Registry entries with no results are listed separately in the trial-records table. This is our search, not a guarantee that no other report exists.

Read together, these reports justify better studies. They don't justify a promise that BPC-157 will heal a tendon, repair your gut, or work in a different form. They also make "there is no human evidence" too strong a statement. The real question for any claim is whether the evidence matches it.

Why "people improved" is not the same as "the treatment worked"

An improvement can be completely real even when a study can't show what caused it. People often start a product at the same time as rest, physical therapy, or other medicines, and many injuries ease with time. A comparison group—people who didn't get BPC-157 but were otherwise treated the same—is how researchers separate a treatment's effect from everything else.

Hypothetical example: Someone with a sore Achilles tendon starts BPC-157, cuts back on running, and begins a new rehab plan. Six weeks later, the pain is much better. Their improvement is real. What's unknown is how much came from the peptide, the rest, the rehab, or time. That's not dismissing their experience—it's the question no single story can answer.

The 2026 preprint shows a second trap: the denominator, or the group a percentage is divided by.

Source: Venkatakrishnan et al., preprint version 1, posted September 7, 2026; checked October 14, 2026. Percentages are Peptide Care Index arithmetic (for example, 279 ÷ 354 = 78.8%; 279 ÷ 1,039 = 26.9%), rounded to one decimal.

A headline like "79% improved" uses only the people whose notes recorded a response. Two of every three users had no recorded response at all—685 missing for every 354 recorded, about 1.9 to 1. Neither 78.8% nor 26.9% is an effectiveness rate. Both describe what happened to get written down. Our BPC-157 news and evidence tracker has the full breakdown and downloadable files.

What this means for you:

• If you want an established treatment, you need stronger outcome evidence than any of these reports provide.
• If you're judging a specific offer, you need the exact product and the exact result it promises, then the human study that matches both.
• If you were just curious, you now have the central answer.

Evidence for a claim is one question. Whether a particular clinic can actually supply BPC-157 to you, and what you'd pay, is a separate one that none of these studies answers. If you're already comparing an offer, Peptide Care Index's Find My Peptide Path tool lays out the dated U.S. access record for BPC-157, the provider details to confirm, and the fee questions to ask before you pay. It's free, with no account or email, and it doesn't approve a treatment or promise that BPC-157 can be supplied.

Find My Peptide Path1

What is BPC-157?

BPC-157 is a synthetic peptide: a chain of 15 amino acids, the building blocks of proteins, made in a lab. Researchers based it on part of a larger protein found in human stomach juice, which is where the name "body protection compound" comes from. The name is a label, not proof that a product protects or heals anything.

A few terms, defined once:

• Peptide: a short chain of amino acids. Insulin and many newer weight-loss drugs are peptides too, but each peptide is a different molecule with its own evidence.
• Synthetic: built in a lab, not extracted from a stomach. Commercial BPC-157 is not a stomach extract.
• Experimental: still being studied; FDA's May 2026 review found no approved BPC-157 medicine in the countries it checked (p. 24–25).

Croatian researchers first described BPC-157 in 1993 (FDA review, p. 22). In studies and on labels you may also see PL 14736, PL-10, or Bepecin. PCO-02 is the investigational tablet product named in the registered oral study, not a separate name for every BPC-157 product. Online it's often nicknamed the "Wolverine peptide," after the comic-book healer—a marketing nickname FDA quotes from a clinic website, not a scientific description (FDA review, p. 23).

Free base, acetate, arginate: why the exact form matters

The same core molecule can come as a free base or in different chemical "packaging" called salts—BPC-157 acetate and, on some capsule labels, BPC-157 arginate. FDA treats free base and acetate as different ingredients, and says it has found multiple salts and look-alike molecules sold under the single name "BPC-157," which means a patient may not get the ingredient a clinician intended (FDA review, p. 9).

A label that only says "BPC-157" names the peptide but leaves the salt and finished formulation unclear. It is not enough to match the bottle to a study or a prescription. For capsule labels and salt claims in detail, see how to read BPC-157 capsule formulations.

A proposed mechanism is a reason to test, not proof

Lab studies suggest several ways BPC-157 might work: encouraging new blood vessels, affecting inflammation signals and nitric oxide, and changing how repair cells behave. FDA notes that BPC-157's actual molecular targets haven't been identified and its mechanisms remain poorly understood (FDA review, p. 31–32).

One concrete example: in a 2014 study of rat tendon cells, BPC-157 increased the number of growth-hormone receptors on those cells. That's an interesting cell result. It does not show that BPC-157 raises growth hormone or testosterone in people, and BPC-157 is not growth hormone.

The chain works like this: a change in cells → a plausible idea → a human study that measures a real outcome. BPC-157 has a lot of the first two steps and very little of the third.

Does BPC-157 help tendon, joint, or muscle injuries?

The human evidence doesn't establish BPC-157 as a dependable treatment for repairing tendons, joints, or muscles. The best human signal is less knee pain in a small look-back review without a comparison group. Pain relief is worth something, but it's a different outcome from a healed tendon.

Most of the injury enthusiasm comes from animals. Researchers have reported faster healing of cut tendons and ligaments in rats (FDA review, p. 30; Cerovecki 2010). Those are surgically injured animals given set amounts by set routes—useful science, not a preview of your Achilles.

The knee review is the human example most often cited, so read it closely (Lee & Padgett 2021):

• It looked back at records; nobody was randomly assigned.
• People had different knee problems.
• It measured whether people said their pain was better, by phone, at different times.
• Twelve people got BPC-157 alone and 11 reported improvement. Four got BPC-157 plus thymosin beta-4. Those four aren't evidence about BPC-157 alone, and the authors' "TB4" does not establish what is in a product sold as TB-500.
• The injections went into the knee joint. That says nothing direct about capsules or shots under the skin.

FDA's 2026 review did not evaluate BPC-157 for tendonitis at all. Tendonitis was one of the nominated uses, but FDA said the nomination didn't include enough information and it found no clinical studies in that group (FDA review, p. 8, footnote 4).

One planned U.S. test of an injury use is the University of Arkansas rotator-cuff study, which plans to give BPC-157 under the skin after surgery. When we checked, it was not yet recruiting, with an estimated start of January 1, 2027 (NCT07803250).

What would convincing injury evidence measure?

A convincing study would compare people with the same diagnosis, give one group BPC-157 and the other a comparison treatment, keep the rest of their care the same, and measure what matters to them over enough time. Less pain alone can't show that a tendon is structurally healed or ready for full sport.

Ask four questions of any injury claim:

1. What diagnosis is being treated? A partial Achilles tear and general knee arthritis are different problems.
2. Does the cited human study match it? Same injury, same route, same kind of product?
3. What improvement counts as success? Less pain, better function, healed tissue, or faster return to sport—and did the study measure that?
4. What established options have you and your clinician considered? Physical therapy, load management, and other treatments have their own evidence.

Does BPC-157 help gut problems?

"Gut health" is too broad to be one proven benefit. The only controlled human study in a gut disease tested a BPC-157 enema in ulcerative colitis for two weeks, and it didn't show a clear difference from placebo. The 2026 clinical-note preprint also records gastrointestinal reasons for use, but it does not establish a benefit for a particular gut disease, product, or route.

The ulcerative colitis trial is worth knowing because it's often described as either proof or as nonexistent. It's neither. Fifty-three people were randomized; the BPC-157 group's disease score dropped more on average than the placebo group's, but the reported range of possible differences included no difference at all, and the details survive only in a short meeting abstract. FDA concluded the data can't support efficacy or safety (FDA review, p. 27).

That study used an enema, which places the drug directly in the lower bowel. A swallowed capsule is a different route, and we found no matching controlled capsule study establishing a gut-disease benefit. The capsule results summary measured pain scores, not a diagnosed digestive disease.

There's an honest wrinkle. BPC-157 might act directly on the gut lining without much entering the blood. The lack of blood-level data doesn't disprove that. But a possible local effect is still a hypothesis, not a clinical result.

If you have ulcerative colitis or Crohn's disease, don't swap or stop your current treatment for BPC-157. FDA notes there are many approved treatments for ulcerative colitis, a disease that can cause life-threatening complications when it isn't controlled (FDA review, p. 28–29). Raise BPC-157 with your gastroenterologist if you're curious.

What does an ad mean by "gut healing"?

Ask which condition and which result the phrase means. A symptom score, a lab marker, and healing seen during a scope are three different findings. Less discomfort alone does not establish that damaged tissue has healed.

Hypothetical example: An ad sells swallowed BPC-157 capsules for "gut repair" and cites a "clinical trial in colitis." The cited trial used an enema, in diagnosed ulcerative colitis, for two weeks, and didn't show a clear benefit. The mismatch runs through the condition, the product, the route, and the result. The useful next question is: "Which human study used this product, for this problem, and measured this outcome?"

For swallowed forms in depth, see what human research on oral BPC-157 shows.

Capsules, injections, and other forms: are they equivalent?

No. A swallowed capsule, a strip held under the tongue, a shot under the skin, and an injection into a joint are different routes, and a finding from one doesn't carry over to another. FDA also notes that immune-reaction concerns are generally higher for under-the-skin and nasal use than for swallowed or rectal use (FDA review, p. 43).

Based on the human reports and registry records on this page, checked October 14, 2026. This is a guide to what each route's evidence covers, not a ranking of routes. "No human study found" means none in our review, not that the route can't work.

Does an arginate, acetate, or "high absorption" label settle it?

A more specific label helps identify the product, but it doesn't prove a better result. The salt form, the release design, how much reaches the blood, and whether it helps are four separate questions, and each needs its own evidence.

Even the capsule summary shows how slippery this is. Its methods describe BPC-157 arginate with SNAC (an ingredient intended to aid absorption) in a delayed-release capsule, while its cover illustration includes an acetate-related marker (summary). We describe the formulation "as reported," not as confirmed. And a lab purity or stomach-acid stability percentage is never the same as a human absorption percentage. Our capsule guide walks through those claims.

Is there an established BPC-157 dose?

No validated treatment dose has been established for the injury or gut-healing claims discussed here. Early healthy-volunteer research did compare several rectal doses for short-term tolerability; that is not the same as finding an effective treatment regimen (FDA review, p. 54). The human reports used enemas, knee-joint injections, bladder-wall injections, IV drips, and one capsule product, but they do not establish a dose to use across those routes.

An amount repeated in marketing or a forum is not a validated treatment dose. Study amounts given by one route can't be converted into a capsule or a shot by another, and animal amounts can't be scaled to people this way either. If a clinician proposes an amount, a fair question is: "What evidence supports this amount, for this product and this route?"

BPC-157 side effects and long-term safety

Nobody knows yet how safe BPC-157 is for people. The small human studies didn't report serious problems, but they were short and tracked safety loosely. FDA's search through December 4, 2025 retrieved three injectable-product reports—an injection-site reaction, shortness of breath, and skin and gum darkening—and FDA flags immune reactions and impurities as real concerns, especially for injected and nasal products (review, p. 41–43).

Three different questions get mixed together here: what the substance itself does, what's actually in a given product, and the risks of how it's given (for example, injecting a non-sterile liquid). Keep them separate.

BPC-157 safety signals: what's reported and what it means

Peptide Care Index summary of the linked records, checked October 14, 2026. FDA's adverse-event search ran through December 4, 2025. An adverse-event report shows that something was reported, not that the product caused it.

People and clinics online also describe nausea, fatigue, and lightheadedness. Those accounts may be real, but we found no study that measured how often they happen, so we don't list them as established side effects.

Does BPC-157 cause cancer?

The evidence reviewed here does not establish whether BPC-157 increases cancer risk in people. FDA's May 2026 review identified no carcinogenicity studies—studies designed to assess whether a substance causes tumors (p. 39). People worry because one proposed way BPC-157 works is by growing new blood vessels, and tumors also rely on new blood vessels. That's a reasonable question, not a finding.

So neither "it causes cancer" nor "it's been shown not to" is supported. If you have cancer now, or have had it, this unknown is worth raising with your oncologist before using BPC-157.

Who should be especially careful?

The small human studies don't give a reliable safety answer for anyone outside them. A few situations call for extra care because of what's known—or specifically unknown:

• Pregnancy or breastfeeding: no human data. One rat study of injections during pregnancy found no birth defects, but FDA did not identify studies covering a complete reproductive cycle (FDA review, p. 38–39).
• Cancer now or in the past: long-term cancer risk in people remains unresolved.
• Blood thinners or a bleeding or clotting condition: animal studies showed changes in a clotting test. That isn't a known human interaction, but it's a specific thing to raise with your clinician.
• Ulcerative colitis or Crohn's disease: don't replace proven treatment.
• Other medicines and conditions: we found no reliable human interaction studies. "No known interactions" is not evidence that a combination is safe.

If you've already used BPC-157

If you have trouble breathing; swelling of your face, lips, tongue, or throat; chest pain; or you faint, call 911 or go to the nearest emergency department now. Do not delay emergency care to collect it; bring or photograph the product only if you can do so safely (MedlinePlus emergency guidance).

For anything less urgent, keep the label, vial or bottle, lot number, where you bought it, how you took it, and the dates. Tell the clinician who's assessing you exactly what you used, including any other peptides or supplements. New symptoms need to be evaluated on their own merits—this page can't tell you whether BPC-157 caused them. You can also report a problem to FDA through MedWatch.

Is BPC-157 FDA approved, and can you get it in the U.S.?

BPC-157 is not FDA-approved as of October 14, 2026. In July an FDA advisory committee voted to recommend letting pharmacies compound it—after FDA's own staff recommended against—but we found no final addition or issued temporary policy naming BPC-157 in the FDA and Federal Register records checked. A clinic ad, a pharmacy's involvement, or that vote is not the same as an approved drug or a confirmed legal supply route.

Two words matter here. FDA approval means FDA reviewed a specific finished drug for a specific use. Compounding means combining, mixing, or altering ingredients to prepare a medicine; section 503A generally concerns patient-specific compounding, while section 503B has a separate outsourcing-facility framework. Compounded drugs are not FDA-approved, and FDA doesn't check their safety, effectiveness, or quality before they're sold (FDA compounding Q&A). The July meeting was about compounding, not approval. Off-label use means using an already approved drug outside its approved labeling; it does not turn an unapproved BPC-157 product into an approved medicine (FDA explanation).

BPC-157 in 2026: what changed and what didn't

Sources linked in each row; checked October 14, 2026.

What the July vote did, and didn't do

The committee gave FDA advice. It didn't approve a drug, and it didn't add BPC-157 to any list. FDA makes its own decision through its own process, and we found no final decision adding BPC-157 to the list in the official records checked.

Two details often get lost. First, the only use FDA formally reviewed was ulcerative colitis—not tendons, joints, or general recovery (FDA review, p. 8). Second, even if BPC-157 is added to the compounding list someday, federal rules say a drug compounded from a listed ingredient still can't be described as FDA-approved (21 CFR 216.23(d)). Being on the list is not a back door to approval.

For the full regulatory detail, see is BPC-157 FDA approved? and our FDA peptide hearing tracker.

Was the BPC-157 "ban" lifted?

"Not FDA-approved" and "banned" aren't the same thing, which is why the internet argues about this. FDA now lists BPC-157 among substances whose compounding nominations were withdrawn, while keeping its safety concerns on record (FDA safety page). Moving to that list is not approval, and it isn't a move into the category FDA lets pharmacies use while it decides.

Under the FDA 503A framework, a bulk ingredient must meet an applicable USP/NF monograph, be a component of an approved drug if no monograph exists, or appear on the final 503A list if neither of those applies. FDA's BPC-157 review found neither a monograph nor an approved-drug component for free base or acetate, and BPC-157 is absent from both the final list and the Category 1 list used in FDA's interim policy we checked. Withdrawal is not permission to compound. We have not verified a specific pharmacy's supply arrangement; a pharmacy claiming an applicable exception or newer policy needs to identify it. These FDA records cover drug approval and pharmacy compounding. They don't answer questions about personal possession, and we don't give legal advice.

One more data point: FDA found no reports of BPC-157 products from outsourcing facilities—larger compounders that must report what they make—from January 2017 through June 2025 (FDA review, p. 23).

What about "research use only" BPC-157?

A "research use only" or "not for human consumption" label means the seller says the product isn't for people. It is not a cheaper version of patient care, and we don't recommend research-chemical sellers as a source of treatment. FDA has warned at least one seller, Warrior Labz, for marketing products including BPC-157 for human use behind research-style disclaimers (FDA warning letter, June 12, 2023). The skin-and-gum-darkening report in FDA's files involved a research-labeled product.

Capsules sold as dietary supplements raise a different problem. FDA notes BPC-157 is marketed that way (FDA review, p. 9), and the Defense Department's supplement-safety program says BPC-157 is not a dietary ingredient (OPSS). A supplement label is not a drug approval.

BPC-157 U.S. access check, requirement by requirement

This uses our Peptide Care Access Check: each row is one requirement, the evidence that applies, and what we found. The labels describe only that requirement—they aren't an overall rating.

Checked October 14, 2026. This is a source review, not a legal opinion on any specific pharmacy, clinic, or purchase.

Do registered trials offer a way to get BPC-157 now?

We did not identify a currently enrolling U.S. option in the registry records checked. A registry entry shows what a study's sponsor submitted; it doesn't guarantee an open spot, and none of the four BPC-157 records we checked has posted results.

Full ClinicalTrials.gov records, checked October 14, 2026. Don't add the enrollment numbers together. "Estimated" means planned. For the registry snapshot and downloads, see our BPC-157 news tracker; for how to check a study before making plans, see how to get BPC-157.

What would actually change the answer

• For approval: an FDA approval record and label for a specific BPC-157 product.
• For pharmacy compounding: a final rule adding BPC-157 to 21 CFR 216.23, or an issued FDA policy that names it, with its scope and start date.
• For effectiveness: adequately reported results from a well-conducted controlled human trial in a defined condition, interpreted for the size and limits of the effect—not merely the existence of posted results.
• Not enough on its own: a headline, a clinic's announcement, an advisory vote, or a trial listing.

None of these records tells you whether a particular clinic can supply BPC-157 to you, which pharmacy would make it, or what you'd owe if nothing is prescribed. Peptide Care Index's Find My Peptide Path tool puts the dated BPC-157 access record—six requirements, each with its source—next to the provider checks and fee questions, so you can see exactly what an offer still needs to answer before you pay. It's free and needs no account or email.

Find My Peptide Path2

BPC-157 vs. TB-500: does adding it help?

The evidence we reviewed doesn't show that adding TB-500 makes BPC-157 work better. They're different peptides that are often sold together as a "stack," and neither is FDA-approved. We found no controlled trial establishing a benefit from a BPC-157 blend with the exact TB-500 fragment discussed below.

The names cause confusion. FDA's 2026 review evaluates TB-500 as an N-acetylated seven-amino-acid fragment of thymosin beta-4, a 43-amino-acid peptide, and identified no clinical studies of that exact fragment (FDA TB-500 review). So, oddly, BPC-157 has published human studies where FDA's review found none for that exact TB-500 fragment. Evidence about full-length thymosin beta-4 doesn't apply to the fragment.

Two details from this page matter here. The knee review's four combination patients received what the authors called thymosin beta-4, not a verified TB-500 product. And FDA's report of skin and gum darkening came from a BPC-157 + TB-500 blend labeled for research only. For a side-by-side of many peptides, see our peptide comparison chart.

Athletes and service members

If you're drug-tested under World Anti-Doping Agency rules, BPC-157 is banned at all times, in and out of competition, in 2026 and in the published 2027 list. A prescription or a change in pharmacy rules doesn't change that. Service members should know it's also on the Defense Department's prohibited supplement-ingredient list.

• WADA: BPC-157 is listed under S0, "non-approved substances" (2026 list, p. 4). The 2027 list keeps it, effective January 1, 2027.
• Exemptions: the U.S. Anti-Doping Agency says a therapeutic use exemption for BPC-157 is unlikely because permitted alternatives exist, and it decides case by case (USADA). Its Drug Reference Line is the place to ask.
• Military: BPC-157 is on the DoD Prohibited Dietary Supplement Ingredients List, regardless of whether it's swallowed, injected, or sprayed.
• Testing: anti-doping scientists have published methods aimed at detecting BPC-157 (FDA review, p. 40).

These rules apply to athletes covered by them, not to every recreational exerciser. Being banned in sport doesn't prove BPC-157 boosts performance.

What to check before paying for BPC-157 care

First pin down what your payment buys: a consultation, a product, or an ongoing plan. Then get the exact substance, the basis for supplying it, and every required charge in writing. A fee the clinic hasn't told you about isn't zero—it's unknown.

What a listed price does—and doesn't—tell you

A listed price is a line on the receipt, not necessarily the full bill. Here is one real, itemized example we recorded, and one hypothetical.

A provider-published price example (checked October 14, 2026): Rx Peps Direct lists a $39 medical review paid at checkout, then $80 for one 5 mL vial labeled 3 mg/mL and $15 overnight shipping paid separately to the dispensing pharmacy after approval (pricing; published formulation). The labeled total is 15 mg: our calculation, 5 mL × 3 mg/mL. The salt is not identified in that listing.

Its refund policy says the $39 review fee becomes nonrefundable once a clinician starts reviewing your intake, even if no prescription is issued; medication refunds are handled separately by the pharmacy. Before review starts, a cancellation refund may be approved—it is not guaranteed. If no prescription is issued, the policy says no medication purchase is required. The pharmacy's separate no-fill refund terms were not available in the pages checked. We cite this as an example of how to read terms. It is unpaid, not a recommendation, and not proof that this product can lawfully be supplied to you. For more published prices and the conditions behind them, see BPC-157 cost.

The pricing page says there is no membership or mandatory recurring plan. Automatic refills are optional; each carries another $39 review fee plus separate pharmacy costs, and the terms say they can be turned off in the dashboard. That does not establish the next refill date or a refund for a review already started. These pages do not establish whether labs or additional follow-up would be required for a particular person or what those would cost; do not treat an unquoted requirement as included.

Hypothetical example (not a real quote): A clinic lists a $100 consultation, $150 for the product, and $20 shipping, and says lab tests are required without giving a price. The charges you can see add up to $270. The full bill is unknown, because the lab charge is missing. It isn't "only $270," and nothing here says how long the product would last.

What is the most useful next step?

Your next step depends on the question you still have, not on whether you buy a peptide. For most people, the most useful move is either a better conversation with a clinician about proven options or a hard look at one specific offer.

You don't need to choose a product to take a useful next step. If an offer is still on the table, Find My Peptide Path keeps the BPC-157 access record, the eight provider checks, the eight fee questions, and a short set of questions to copy or print in one place, so you can see what that offer still hasn't answered. It's free with no account or email, and it's information, not a prescription or a provider match.

Find My Peptide Path3

What we actually checked

We compared what each source can actually show with the claim a reader might take from it. Each result stays attached to its study design, people, form, route, and follow-up period. This is an editorial source review, not clinical testing or a legal opinion.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we checked, October 14, 2026: FDA's BPC-157 staff review (dated May 11, 2026), the July 2026 advisory meeting page, FDA's compounding safety page and 503A framework, the version of 21 CFR 216.23 displayed current through October 13, 2026, and FDA's Category 1 list; original papers or summaries for the knee, bladder, IV, and capsule reports; the 2026 preprint (version 1); four full ClinicalTrials.gov records; WADA's 2026 and 2027 lists; USADA and Defense Department supplement-safety pages; and one provider's published formulation, prices, refill terms, and refund policy.

Read only through FDA's summary: the 2002–2003 volunteer abstracts and the 2005 ulcerative colitis abstract.

Source limits: the July vote tally remains attributed to ABC News; an official roll-call record was not located. The original October 7 Washington Post report was read directly. For military status, we read OPSS's BPC-157 page, not an independently retrieved row from its dynamic ingredient-list database.

Not done: no product testing, purchases, provider or study-team contact, license checks, pharmacy inspections, or state-by-state checks. Provider prices and terms are what the provider publishes. No clinician, pharmacist, or regulatory specialist reviewed this page. AI assisted the research and drafting, as described in our editorial standards.

Dates: "Sources checked" is the date we inspected the cited material, not a claim that every underlying dataset was updated that day. FDA's safety searches largely end in December 2025; the trial records each retain their own update dates. Each source has its own publication date, shown beside it.

Two kinds of labels appear on this page. The claim check rates how strong the human evidence is for a health claim. The access table uses our Peptide Care Access Check, which follows one requirement at a time—the evidence, the check, the finding, the next question, and what would change it—and labels each finding Supported, Contradicted, Unresolved, Conflicting, or Not applicable. Neither is a safety badge or a provider rating.

Provider links on this page are ordinary, unpaid source links. See how we make money. To point out an error or a changed source, use contact and corrections.

To cite this page: Peptide Care Index. "BPC-157: benefits vs. human evidence, side effects, and FDA status in 2026." Sources checked October 14, 2026. https://peptidecareindex.com/bpc-157/. For a specific table, add its section link, such as #bpc-157-claim-check or #bpc-157-human-reports. You may reuse our original tables and calculations with credit to Peptide Care Index; underlying sources keep their own terms.

Other questions about BPC-157

Is BPC-157 a steroid or growth hormone?

No. BPC-157 is a short peptide, not an anabolic steroid and not growth hormone. The rat tendon-cell study that found more growth-hormone receptors on those cells doesn't show that BPC-157 raises hormones in people (Chang et al., 2014).

How long does BPC-157 take to work?

No reliable timeline exists. The capsule summary measured pain at four weeks, the IV pilot lasted three days, and the knee review followed people for varying lengths of time. A study's measuring point isn't a promise that anything works by that date.

Why is it called the "Wolverine peptide"?

It's a marketing nickname borrowed from the comic-book character who heals quickly. FDA's review quotes a clinic website using it (FDA review, p. 23). It isn't based on human results.

Is BPC-157 approved anywhere outside the U.S.?

FDA's May 2026 review found no approved BPC-157 product in any country it checked. It also notes that New Zealand's medicines classification committee proposed in May 2023 that BPC-157 be classed as a prescription medicine (FDA review, p. 24–25).

Is BPC-157 natural?

Its sequence comes from a protein in human stomach juice, but the BPC-157 sold today is made in a lab. "Natural" doesn't mean tested, and it doesn't mean safe.

Sources and check dates

The sources below support the findings checked October 14, 2026; the reading limits described above still apply. Publication or version dates are listed where known.

1. U.S. Food and Drug Administration. Evaluation of BPC-157-related bulk drug substances (BPC-157 free base and BPC-157 acetate). Staff evaluation dated May 11, 2026, for the July 23–24, 2026 advisory meeting. Pages cited: 8–9, 14–25, 27–32, 38–43, 47, 54. Staff analysis, not a final agency decision.

2. U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Agenda, evaluated uses, and the statement that advice is nonbinding.

3. Electronic Code of Federal Regulations. 21 CFR 216.23, bulk drug substances for compounding under section 503A. Version displayed current through October 13, 2026, inspected October 14; paragraphs (a) and (d).

4. U.S. Food and Drug Administration. Certain bulk drug substances that may present significant safety risks. BPC-157 row in the withdrawn-nominations table.

5. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A. Ingredient conditions and interim policy.

6. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers.

7. Federal Register. Pharmacy Compounding Advisory Committee; notice of meeting. April 16, 2026.

8. ABC News. FDA advisory committee votes to add popular peptide BPC-157. July 23, 2026. Source of the 8–6–1 vote tally.

9. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 2021.

10. OvationLab. BPC-157 capsule results summary. Dated August 22, 2024; page 5. Commercial relationship disclosed at ovationlab.com.

11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Alternative Therapies in Health and Medicine, 2024; page 3.

12. Lee E, Burgess K. Safety of intravenous infusion of BPC 157 in humans: a pilot study. Alternative Therapies in Health and Medicine, 2025; page 3.

13. Venkatakrishnan AJ, et al. Rising use of unapproved BPC-157 and associated patient-reported outcomes curated from clinical notes. Preprint version 1, September 7, 2026; not peer reviewed.

14. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014.

15. Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research, 2010. Abstract-level access.

16. ClinicalTrials.gov records: NCT07803250 (last updated Sep 3, 2026); NCT07437547 (Feb 27, 2026); NCT07752381 (Aug 7, 2026); NCT02637284 (Dec 22, 2015).

17. U.S. Food and Drug Administration. TB-500 evaluation for the July 2026 meeting. Staff evaluation dated May 15, 2026.

18. World Anti-Doping Agency. 2026 Prohibited List, page 4; 2027 Prohibited List, effective January 1, 2027.

19. U.S. Anti-Doping Agency. BPC-157: what athletes should know. Updated August 10, 2026.

20. Operation Supplement Safety (Department of Defense). BPC-157: a prohibited peptide and an unapproved drug. Posted April 29, 2025.

21. U.S. Food and Drug Administration. Warning letter to Warrior Labz SARMS. June 12, 2023.

22. The Washington Post. Report on a possible temporary pathway for unapproved peptides. October 7, 2026. Original report inspected; no issued policy is established by this reporting.

23. KFF Health News. Patients' accounts of harm from experimental peptides. October 13, 2026. The Washington Post, people who have taken unregulated peptides, October 13, 2026.

24. Rx Peps Direct. Pricing, formulary, terms, and refund policy. Provider-published; no checkout, order, or pharmacy-policy verification.

25. U.S. Food and Drug Administration. MedWatch safety reporting.

26. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. List updated May 14, 2026; Category 1 checked for BPC-157.

27. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs (off label).

28. MedlinePlus. Anaphylaxis. Emergency signs and response; not a BPC-157-specific adverse-effect list.

29. World Anti-Doping Agency. WADA publishes 2027 Prohibited List. September 21, 2026; list takes effect January 1, 2027.